Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Epix Pharmaceuticals, Inc.
Patients with major depressive disorder who meet all of the eligibility criteria will be randomly assigned to receive twice daily doses of either placebo or PRX-00023. Study drug will be taken for up to approximately 9 weeks. Patients will have periodic office visits for the purpose of monitoring safety and tolerability, as well as efficacy assessments.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of major depressive disorder
You may not be if
Females who are pregnant or nursing
Electroconvulsive therapy within previous year
Type 1 diabetes or uncontrolled type 2 diabetes
HIV, Hepatitis B or Hepatitis C
Use of illegal drugs, history of drug abuse, and/or alcohol dependence
Clinically significant abnormal lab results
Other protocol-defined eligibility criteria may apply.
Clareo Health | A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder
